Get to know our clinical trials

Phase I clinical trial to evaluate ZW191 in participants with advanced solid tumors

THE PRIMARY OBJECTIVE IS TO EVALUATE THE SAFETY AND TOLERABILITY OF ZW191 AND DETERMINE THE DMT AND DRES OF ZW191 IN DIFFERENT TUMOR TYPES.

Imagen del Dr. Antonio González Martín, director del Departamento de Oncología Médica de la Clínica Universidad de Navarra
Dr. Antonio González Curriculum
Director Medical Oncology Department
Madrid headquarters
Cancer Center
Gynecologic Cancer Area
Status
In recruitment
headquarters
Madrid
Early phase

Technical Summary

  • PHASE I, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF ASCENDING DOSES OF AN ANTIBODY-DRUG CONJUGATE TARGETING FOLATE RECEPTOR A, ZW191, IN PARTICIPANTS WITH ADVANCED SOLID TUMORS.
  • Code EudraCT: 2024-512299-37-00
  • Protocol number: ZWI-ZW191-101
  • Promoter: Zymeworks BC Inc.
  • Molecule/Drug: ZW191

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION